Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Myokardia Inc (MYOK)

Myokardia Inc (MYOK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,992,876
  • Shares Outstanding, K 53,323
  • Annual Sales, $ 0 K
  • Annual Income, $ -276,210 K
  • 60-Month Beta 1.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 14.11
Trade MYOK with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -5.64
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/09/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -1.41
  • Number of Estimates 4
  • High Estimate -1.10
  • Low Estimate -1.68
  • Prior Year -1.27
  • Growth Rate Est. (year over year) -11.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
221.90 +1.36%
on 10/20/20
225.00 -0.04%
on 11/16/20
+2.91 (+1.31%)
since 10/16/20
3-Month
97.83 +129.90%
on 08/20/20
225.00 -0.04%
on 11/16/20
+125.67 (+126.63%)
since 08/14/20
52-Week
42.65 +427.34%
on 04/02/20
225.00 -0.04%
on 11/16/20
+169.96 (+309.30%)
since 11/15/19

Most Recent Stories

More News
MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten

EXPLORER -HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation

MYOK : 224.91 (+0.05%)
MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020

ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients

MYOK : 224.91 (+0.05%)
MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy

Registry to Enable Prospective Safety Study “DISCOVER-HCM” to Track Long-Term Safety and Effectiveness of Mavacamten in Patients with Symptomatic, Obstructive Hypertrophic Cardiomyopathy

MYOK : 224.91 (+0.05%)
MDRX : 17.50 (+2.28%)
MyoKardia Reports Third Quarter 2020 Financial Results

Acquisition of MyoKardia by Bristol-Myers Squibb Expected to Close During 4th Quarter of 2020

MYOK : 224.91 (+0.05%)
Bristol Myers Squibb Reports Third Quarter 2020 Financial Results

Bristol Myers Squibb (NYSE:BMY) today reports results for the third quarter of 2020, which reflect strong product sales, continued pipeline advancement and robust operating performance.

BMY : 75.57 (+1.49%)
EXEL : 19.48 (+1.30%)
BLUE : 6.72 (+6.50%)
MYOK : 224.91 (+0.05%)
MyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants Program

BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000...

MYOK : 224.91 (+0.05%)
Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period

Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection...

BMY : 75.57 (+1.49%)
MYOK : 224.91 (+0.05%)
MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 2020

EXPLORER Cardiac MRI Substudy Selected as Featured Scientific Presentation

MYOK : 224.91 (+0.05%)
ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations - CIT, MYOK, CBMG, PRCP

NEW YORK, NY / ACCESSWIRE / October 29, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: CIT Group Inc. (NYSE:CIT) concerning potential violations of the federal...

CIT : 53.50 (+4.21%)
MYOK : 224.91 (+0.05%)
CBMG : 19.75 (unch)
PRCP : 6.98 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP is Investigating the Following Companies; Investors are Encouraged to Contact the Firm – STND, MYOK, EIDX, WTRE

NEW YORK, NY / ACCESSWIRE / October 24, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating: Standard AVB Financial Corp. (NASDAQ:STND) concerning potential violations of the federal...

STND : 33.00 (+0.06%)
MYOK : 224.91 (+0.05%)
EIDX : 122.21 (-4.85%)
WTRE : 20.03 (+0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 225.29
1st Resistance Point 225.10
Last Price 224.91
1st Support Level 224.62
2nd Support Level 224.33
3rd Support Level N/A

See More

52-Week High 225.00
Last Price 224.91
Fibonacci 61.8% 155.34
Fibonacci 50% 133.82
Fibonacci 38.2% 112.31
52-Week Low 42.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar